PMC Articles for PubChem Compound (Select 58282870) - PMC

Result Filters

Links from PubChem Compound

Items: 3

Select item 102899571.

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors

Anastasios Stathis, Anthony W. Tolcher, Judy S. Wang, Daniel J. Renouf, Lin-Chi Chen, Leah H. Suttner, Tomoko Freshwater, Andrea L. Webber, Tapan Nayak, Lillian L. Siu

Invest New Drugs. 2023; 41(3): 380–390. Published online 2023 Apr 11. doi: 10.1007/s10637-022-01326-3

PMCID:: PMC10289957

Abstract Article PDF–1.1M

Select item 85087662.

Selective Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibition by the SCH772984 Compound Attenuates In Vitro and In Vivo Inflammatory Responses and Prolongs Survival in Murine Sepsis Models

Michal Kopczynski, Izabela Rumienczyk, Maria Kulecka, Małgorzata Statkiewicz, Kazimiera Pysniak, Zuzanna Sandowska-Markiewicz, Urszula Wojcik-Trechcinska, Krzysztof Goryca, Karolina Pyziak, Eliza Majewska, Magdalena Masiejczyk, Katarzyna Wojcik-Jaszczynska, Tomasz Rzymski, Karol Bomsztyk, Jerzy Ostrowski, Michal Mikula

Int J Mol Sci. 2021 Oct; 22(19): 10204. Published online 2021 Sep 22. doi: 10.3390/ijms221910204

PMCID:: PMC8508766

Abstract Article PDF–2.2M

Select item 59162433.

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

Stergios J. Moschos, Ryan J. Sullivan, Wen-Jen Hwu, Ramesh K. Ramanathan, Alex A. Adjei, Peter C. Fong, Ronnie Shapira-Frommer, Hussein A. Tawbi, Joseph Rubino, Thomas S. Rush, III, Da Zhang, Nathan R. Miselis, Ahmed A. Samatar, Patrick Chun, Eric H. Rubin, James Schiller, Brian J. Long, Priya Dayananth, Donna Carr, Paul Kirschmeier, W. Robert Bishop, Yongqi Deng, Alan Cooper, Gerald W. Shipps, Blanca Homet Moreno, Lidia Robert, Antoni Ribas, Keith T. Flaherty

JCI Insight. 2018 Feb 22; 3(4): e92352. Published online 2018 Feb 22. doi: 10.1172/jci.insight.92352